Donald Hooker
Stock Analyst at Keybanc
(2.52)
# 1,500
Out of 4,829 analysts
82
Total ratings
53.06%
Success rate
8.41%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $7.35 | +1,260.54% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $143.08 | +172.57% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $175.90 | -3.35% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $156.13 | +85.74% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $26.05 | +180.23% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $4.64 | +675.86% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $7.21 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $241.44 | +46.21% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $96.66 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $76.80 | +9.38% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $9.31 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $250.94 | -32.25% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $140.22 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $1.52 | +2,926.32% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $23.01 | - | 1 | Oct 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $313.74 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $7.35
Upside: +1,260.54%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $143.08
Upside: +172.57%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $175.90
Upside: -3.35%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $156.13
Upside: +85.74%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $26.05
Upside: +180.23%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $4.64
Upside: +675.86%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $7.21
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $241.44
Upside: +46.21%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $96.66
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $76.80
Upside: +9.38%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $9.31
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $250.94
Upside: -32.25%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $140.22
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $1.52
Upside: +2,926.32%
Oct 24, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $23.01
Upside: -
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $313.74
Upside: -